Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized Budesonide vs Oral Corticosteroids for Wheezing Relapse in Pediatric Patients
NCT00189436Phase 4Completed
- Sponsor
- Gentile Allergy and Asthma
- Start
- Mar 2003
- Primary completion
- Jan 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of EPI-EE in asthma (2 arms), sponsored by Gentile Allergy and Asthma. Primary endpoint: Wheezing/Asthma/Bronchospasm Relapse Rate at 3 weeks. Started Mar 2003; status: completed.
02
Drugs
EPI-EE
03
Conditions
asthma
Beyond the preview
Go deeper on NCT00189436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00189436.